# US 2025/0084466 A1 · Devices, kits, and methods for determining increased susceptibility to and treatment and prevention of periodontitis, alzheimer’s disease, and other conditions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0084466 A1
- Document ID: US20250084466A1
- Status: Published application
- Kind: A1
- Application number: 18/958,170
- Filed: 2024-11-25
- Published: 2025-03-13
- Earliest claimed: 2021-07-08
- Assignees: Semmelweis Egyetem
- Applicants: Semmelweis Egyetem
- Inventors: Martin Levine; Zsolt M. Lohinai; Anna Zsuzsanna FÖldes
- Web page: https://patentgrep.com/patent/US20250084466A1

## CPC

- C12Q 1/6827: for detection of mutation or polymorphism
- A61K 33/16: Fluorine compounds
- A61K 33/30: Zinc; Compounds thereof
- B01L 3/502715: {characterised by interfacing components, e.g. fluidic, electrical, optical or mechanical interfaces}
- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- B01L: CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE

## Abstract

Diagnostic microarray devices, kits, and methods of treating or reducing the occurrence of various conditions or diseases are disclosed, wherein the conditions or diseases include (but are not limited to) periodontal disease, Alzheimer's disease, cardiovascular disease, arthritis, and adverse pregnancy outcomes. The devices, kits, and methods utilize an analysis of single nucleotide polymorphisms (SNPs) from various interleukins.

## Claims

### Claim 1

A diagnostic microarray device, comprising:
a substrate formed of a glass material;
at least sixteen probes attached or otherwise associated with the substrate, wherein each probe is associated with the substrate at a defined location for detection thereof, wherein each probe is specific to one allele of a single nucleotide polymorphism (SNP), and wherein the at least sixteen probes comprise:
a probe that detects a G allele of IL1A-889;
a probe that detects an A allele of IL1A-889;
a probe that detects a C allele of IL1B+3877;
a probe that detects a T allele of IL1B+3877;
a probe that detects a G allele of IL1B-511;
a probe that detects an A allele of IL1B-511;
a probe that detects a G allele of IL6-1363;
a probe that detects a T allele of IL6-1363;
a probe that detects a G allele of IL10-597;
a probe that detects a T allele of IL10-597;
a probe that detects a G allele of CD14-260;
a probe that detects an A allele of CD14-260;
a probe that detects an A allele of COX2+8473; and
a probe that detects a G allele of COX2+8473.

### Claim 2 (depends on 1)

The diagnostic microarray device of claim 1, further defined as a diagnostic microarray device for detecting susceptibility to periodontal disease.

### Claim 3 (depends on 1)

The diagnostic microarray device of claim 1, further defined as a diagnostic microarray device for detecting susceptibility to Alzheimer's disease.

### Claim 4 (depends on 1)

The diagnostic microarray device of claim 1, further defined as a diagnostic microarray device for detecting susceptibility to cardiovascular disease.

### Claim 5 (depends on 1)

The diagnostic microarray device of claim 1, further defined as a diagnostic microarray device for detecting susceptibility to arthritis.

### Claim 6 (depends on 1)

The diagnostic microarray device of claim 1, further defined as a diagnostic microarray device for detecting susceptibility to adverse pregnancy outcomes.

### Claim 7 (depends on 1)

The diagnostic microarray device of claim 1, wherein the substrate is formed of a glass ionomer material.

### Claim 8 (depends on 1)

The diagnostic microarray device of claim 1, further defined as comprising at least eighteen probes, and wherein the at least eighteen probes further comprise at least two of:
a probe that detects an A allele of MMP8-799;
a probe that detects a G allele of MMP8-799;
a probe that detects a C allele of IL10-1082; and
a probe that detects a T allele of IL10-1082.

### Claim 9 (depends on 1)

A method of treating or reducing the occurrence of periodontal disease in a subject, the method comprising the steps of:
contacting the diagnostic microarray device of claim 1 with at least a portion of a biological sample from the subject and incubating the diagnostic microarray device under conditions that allow for detection of nucleic acid bound to any of the probes associated with the substrate of the diagnostic microarray device;
determining the alleles present for each of the SNPs IL1A-889, IL1B+3877, IL1B-511, IL6-1363, IL10-597, CD14-260, and COX2+8473 to define a genotype for the biological sample;
administering at least one therapeutic agent and/or recommending at least one therapeutic protocol to the subject when:
(i) the genotype for the biological sample comprises IL1B+3877CT and IL1B-511GG;
(ii) the genotype for the biological sample comprises IL1B+3877CT and IL1B-511GA, and wherein the genotype does not contain any of the following alleles: IL6-1363T, and COX2+8473G; or
(iii) the genotype for the biological sample comprises IL1B+3877CC, IL1B-511GA, and IL6-1363GT.

### Claim 10 (depends on 9)

The method of claim 9, wherein the at least one therapeutic agent comprises at least one of a furzinc oxide/zinc citrate toothpaste and a stannous fluoride toothpaste.

### Claim 11 (depends on 9)

The method of claim 9, wherein the at least one therapeutic agent comprises Atuzaginstat (COR388).

### Claim 12 (depends on 9)

The method of claim 9, wherein the at least one therapeutic protocol comprises performing dental scaling and root planing at least about once every three months.

### Claim 13 (depends on 1)

A method of treating or reducing the occurrence of Alzheimer's disease in a subject, the method comprising the steps of:
contacting the diagnostic microarray device of claim 1 with a biological sample from the subject and incubating the diagnostic microarray device under conditions that allow for detection of nucleic acid bound to any of the probes;
determining the alleles present for each of the SNPs IL1A-889, IL1B+3877, IL1B-511, IL6-1363, IL10-597, CD14-260, COX2+8473 to define a genotype for the biological sample;
administering at least one therapeutic agent and/or recommending at least one therapeutic protocol to the subject when:
(i) the genotype for the biological sample comprises IL1B+3877CT and IL1B-511GG;
(ii) the genotype for the biological sample comprises IL1B+3877CT and IL1B-511GA, and wherein the genotype does not contain any of the following alleles: IL6-1363T, and COX2+8473G; or
(iii) the genotype for the biological sample comprises IL1B+3877CC, IL1B-511GA, and IL6-1363GT.

### Claim 14 (depends on 13)

The method of claim 13, wherein the at least one therapeutic agent comprises at least one of a furzinc oxide/zinc citrate toothpaste and a stannous fluoride toothpaste.

### Claim 15 (depends on 13)

The method of claim 13, wherein the at least one therapeutic agent comprises Atuzaginstat (COR388).

### Claim 16 (depends on 13)

The method of claim 13, wherein the at least one therapeutic protocol comprises performing dental scaling and root planing at least about once every three months.

### Claim 17 (depends on 1)

A method of treating or reducing the occurrence of at least one of cardiovascular disease, arthritis, and adverse pregnancy outcomes in a subject, the method comprising the steps of:
contacting the diagnostic microarray device of claim 1 with a biological sample from the subject and incubating the diagnostic microarray device under conditions that allow for detection of nucleic acid bound to any of the probes;
determining the alleles present for each of the SNPs IL1A-889, IL1B+3877, IL1B-511, IL6-1363, IL10-597, CD14-260, COX2+8473 to define a genotype for the biological sample;
administering at least one therapeutic agent and/or recommending at least one therapeutic protocol to the subject when:
(i) the genotype for the biological sample comprises IL1B+3877CT and IL1B-511GG;
(ii) the genotype for the biological sample comprises IL1B+3877CT and IL1B-511GA, and wherein the genotype does not contain any of the following alleles: IL6-1363T, and COX2+8473G; or
(iii) the genotype for the biological sample comprises IL1B+3877CC, IL1B-511GA, and IL6-1363GT.

### Claim 18 (depends on 17)

The method of claim 17, wherein the at least one therapeutic agent comprises at least one of a furzinc oxide/zinc citrate toothpaste and a stannous fluoride toothpaste.

### Claim 19 (depends on 17)

The method of claim 17, wherein the at least one therapeutic agent comprises Atuzaginstat (COR388).

### Claim 20 (depends on 17)

The method of claim 17, wherein the at least one therapeutic protocol comprises performing dental scaling and root planing at least about once every three months.
